Please assess the completion status of the following clinical trial:

Trial Title: Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple Myeloma in first relapse.~* In Complete or very good partial remission~* Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg~Exclusion Criteria:~* Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus~* Previous Total body irradiation~* Any previous radiation dose to the spinal cord which could reach to 45gy equivalent, including the proposed TBMI~* Amyloidosis~* Brain localizations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Total BM irradiation dose (Type: EXPERIMENTAL): Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication.

Based on this trial design, predict the completion outcome and termination type (if applicable).